Stock Report

Download full stock data and analysis for free Last Updated: 05-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Onconova Therapeutics (ONTX) Key Ratios

Stock Card factsheet share-fund-plan-icon

$14.33

up-down-arrow $6.40 (80.69%)

As on 04-Sep-2026 12:17EDT

Market cap

info icon

$21 Mln

Revenue (TTM)

info icon

$0 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

1.9

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 0.00 0.00 0.00 -1.29 -20.75
EBIT -- 27.29 34.54 11.58 7.23
Net Profit 0.00 22.70 10.97 9.13 3.56
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -8,321.68-7,355.70-6,267.70-8,981.42-8,684.51
Net Margin info ---18,166.24-7,680.09----
Return on equity info -68.98-148.79-137.81-97.22-49.18
Return on Capital info -68.98-148.79---97.22-49.18
Return on Assets info -47.20-72.05-38.73-61.07-38.59
Debt to Equity (x) info ----0.00----

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
-97.22
-49.18
-60.53
-283.48
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-137.81

Lower than Peers by 156.79

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
-137.81
-97.22
-49.18
-60.53
-283.48
Peer Median
18.97
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-38.73

Lower than Peers by 41.59

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
-38.73
-61.07
-38.59
-41.95
-115.24
Peer Median
2.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-6,267.70

Lower than Peers by 6,283.52

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
-6,267.70
-8,981.42
-8,684.51
-7,299.12
-10,819.48
Peer Median
15.82
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-7,680.09

Lower than Peers by 7,688.32

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
-7,680.09
-8,384.07
-8,097.79
-7,003.54
-35,432.39
Peer Median
8.23
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.59

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
-0.59
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

--

--

Year on year growth in net sales

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
--
--
-0.02
-0.89
Peer Median
8.05
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

34.54

Higher than Peers by 26.28

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
34.54
-3.42
-18.98
34.00
-15.18
Peer Median
8.26
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

10.97

Higher than Peers by 3.24

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
10.97
-3.54
-15.62
37.08
-16.99
Peer Median
7.73
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
--
--
--
--
Peer Median
0.59
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
316,247.81
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

2.46

Higher than Peers by 0.81

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
2.46
2.46
4.89
9.06
1.97
Peer Median
1.65
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

2.30

Higher than Peers by 1.10

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
2.30
2.30
4.88
9.06
1.97
Peer Median
1.20
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

--

--

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
--
-1,401.93
-49.24
-70.40
Peer Median
4.77
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

7.96

Lower than Peers by 13.31

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
7.96
7.96
12.83
12.39
16.02
Peer Median
21.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.01

Lower than Peers by 0.39

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
0.01
0.01
0.00
0.01
0.01
Peer Median
0.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
37.98
46.06
52.52
106.73
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
0.00
1,643.63
1,552.31
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
-0.01
86,316.40
99,008.84
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
37.99
-84,626.72
-97,404.00
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

1.86

Lower than Peers by 5.90

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
1.86
--
--
--
--
Peer Median
7.75
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
--
--
--
--
--
Peer Median
0.50
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.05

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
0.05
1.03
1.98
3.27
0.77
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

21

Lower than Peers by 2,500

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Onconova Therapeutics (ONTX)
21
--
--
--
--
Peer Median
2,521
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...